

## HSOA Journal of Clinical Immunology and Immunotherapy

## **Short Commentary**

## Geriatric Patients with COVID-19 Infection

Gala Serra Carlos\*, Vasquez Camacho Milagritos Margot and Alvarez Gomez Esther

Geriatric Unit, San José Hospital, Teruel, Spain

SARS-CoV-2 is an RNA virus, one of the five human coronaviruses of Beta coronavirus genius, which has expanded to humans from a zoonotic source, probably from bats or pangolins. It is a human transmission infection through droplets and the virus joins the pneumocytes type IIACE2 receptors, with an incubation period from 3 upto 12 days. Asymptomatic course has also been reported, making the infection more difficult to contain [1].

The outbreak of a typical pneumonia in Wuhan in December 2019, prompted the discovery of acute respiratory distress syndrome (ARDS) produced by SARS-CoV-2. World Health Organization (WHO) declared a global pandemic on 11<sup>th</sup> of March 2020. By September 23<sup>th</sup>, 2020, 31,375,325 cases had been confirmed and 966.399 deaths reported all around the world [2]. Spain has been one of the most affected countries, with more than 600,000 infected subjects and more than 30,000 deaths registered until the end of September 2020 [3].

Elderly patients are the most vulnerable part of the population [4]. Based on current epidemiological data, SARS-CoV2-infected patients aged above 80 are at a great greater risk of death compared to younger patients [5]. In a review carried out in Italy on 355 patients, the mean age at the moment of the death was 79.5 years, and in the Chinese WHO report published in March, almost the 22% of the patients infected above 80, died [6,7].

Findings suggest different risk factors to blame for worse clinical outcome and higher mortality in elderly COVID-19 patients. Advanced age remains to be the highest independent risk factor associated with mortality [8]. Hypertension, DM2, cardiovascular diseases, COPD and chronic renal failure, were also found to be risk factors in an American sample [9]. Malesex, older age, leukocytosis, high lactate dehydrogenase level, cardiac injury and hyper glycemia were associated also with death in patients with severe COVID-19 in a Chinese sample [10].

\*Corresponding author: Gala Serra Carlos, Geriatric Unit, San José Hospital, Teruel, Spain, E-mail: galaserracarlos@gmail.com

Citation: Gala-Serra C, Margot VCM, Esther AG (2020) Geriatric Patients with COVID-19 Infection. J Clin Immunol Immunother 6: 047.

Received: October 16, 2020; Accepted: October 20, 2020; Published: October 27, 2020

**Copyright:** © 2020 Gala-Serra C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

On admission, the most frequent symptoms in elderly patients included fever, cough, dyspnea, fatigue, and myalgia and few of them develop an acute respiratory distress syndrome (ARDS) [11]. Elderly patients with COVID-19 may have a typical presentation, fatigue, myalgia, headache, or digestive symptoms, alone, including an orexia, vomiting without fever, or cough. Combined with chronic medical illnesses, the possibility of a typical symptoms, and high incidence of severe illness, elderly patients do require considerably much more attention and nursing during the COVID-19 pandemic [12]. In the case of very elderly patients (older than 90 years-old), death rate was similar to that reported in younger patients, however, the very-elderly patients manifested in or clinical symptoms and a typical changes in the X-ray studies [13].

Laboratory findings frequently show lymphopenia, in 30 to 70% of the cases, with normal or abnormal leukocytes; the lower the lymphocyte count, the more serious the prognosis is. Rising of RCP, ferritin, transaminases, bilirubin, D-Dimer (almost 40% of the cases) and LDH with decrease of albumin are also typical laboratory findings in COVID-19 infection. The abnormal albumin and LDH suggest that SARS-CoV-2 infection is associated with extra pulmonary organ injury, including hepatic injury or myocardial injury [12]. A high level of procalcitonine is un likely. A recent study indicated a high pro inflammatory cytokine storm (including high levels of IL-6, IL- 10, IL-2, and IFN- $\gamma$ ) in severe COVID-19 patients [14].

The most common complications in geriatric COVID-19 patients are: sepsis, respiratory and cardio vascular complications. Patients with cardiac conditions are a special vulnerable group [15].

Respiratory co infections rise the severity and mortality with COVID-19, almost 50% of these patients have it [5] and around 70% precise antibiotics as Ceftriaxone [5,16].

In Wang et al. series, 16.7 % of COVID-19 patients developed arrhythmia, 7.2% myocardiac injury and 8.7% Cardiogenic shock; these figures were higher in critically ill patients [17]. In these cases, high trop on in and natriuretic peptide levels were described. Myocardial injury and heart failure are common and responsible for up 40% of the mortality in these patients [18].

Because elderly patients are prone to multi-organ system dysfunction, it becomes increasingly important to prevent other systemic complications, including gastro intestinal bleeding, renal failure, disseminated intra vascular coagulation (DIC) or deep vein thrombosis and delirium [19].

No specific treatment has been officially recommended for the SARS-Cov2 infection. Up to this day, no antiviral treatment provided clear effectiveness in patients with COVID-19. The most effective approach to control this disease is early diagnosis, effective quarantine and life support treatments. Non-steroidal anti-inflammatory drugs, and ACE/ARB inhibitors, were initially considered but later abandoned [20,21].

Remdesivir, an inhibitor of the viral RNA-dependent RNA-polymerase, was identified early as a promising anti viral drug for Covid-19 becoming the first treatment approved in that indication by the FDA and EMA. Remdesivir reduces the time to recovery or clinical improvement, none the less, has not been shown to reduce mortality [22-28].

Lopinavir-ritonavir, a HIV-1 protease inhibitor, has been suggested as a treatment due to *in-vitro* inhibitory activity against SARS-CoV-2. Recent studies have not found evidence to support the use of lopinavir-ritonavir for treatment of patients with COVID-19 [25,29]. Treatment with hydroxyl chloroquine, an anti malarial drug, also showed a beneficial effect in vitro against SARS-CoV-2. However, it has not showed a clinical beneficial effect or an improvement in the survival with important adverse effects as enlargement of the QT interval and the possibility of secondary arrhythmias [22,28]. Combination between Ceftriax one and Azithromycin, an antibiotic with immune modulatory and anti-inflammatory effect has been also used; a study published in March 2020 showed some improvement in the infection parameters however, further studies have not showed this effect [22,23].

Up to now, dexamet has one is the only drug that has shown to reduce mortality of COVID-19 patients with acute respiratory distress syndrome (ARDS), especially among those receiving invasive mechanical ventilation [24].

Other drugs have been proposed to be effective against SARS-CoV-2 like monoclonal antibodies, anti-IL-6 (tocilizumab, sarilumab and siltuximab), and anti-IL1 (anakinra), Januskinase inhibitors (baricitinib, ruxolitinib) or interfer on beta-1b and alfa-2a. Clinical controlled trials are needed to demonstrate the efficacy of these treatments against the COVID-19 infections.

## References

- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, et al. (2020) Estimation of the asymptomatic ratio of novel Coronavirus infections (COVID19). Int J Infect Dis.
- 2. https://www.who.int/emergencies/diseases/novel-coronavirus 2019
- 3. https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertas-Actual/nCov/situacionActual.html.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 382: 1708-1720.
- Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395: 1054-1062.
- https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019\_17\_marzov2.pdf.
- https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-oncovid-19-final-report.pdf.
- Leung C (2020) Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol 30: e2103.
- Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, et al. (2020) Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 323: 1612-1614.
- Li X, Xu S, Yu M, Wang K, Tao Y, et al. (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146: 110-118.

- Shahid Z, Kalayanamitra R, Mc Clafferty B, Kepko D, Ramgobin D, et al. (2020) COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 68: 926-929.
- Guo T, Shen Q, Guo W, He W, Li J, et al. (2020) Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province, China: A Multicenter, Retrospective Study. Gerontology 66: 467-475.
- Rui L, Sirui L, Xuebei D, Xujun Y, Yanggan W (2020) Clinical observations in very elderly patients with COVID-19 in Wuhan. Geriatr Gerontol Int 20: 709-714.
- 14. Jing L, Sumeng L, Jia L, Wang X, Wang H, et al. (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV-2 infected patients. medRxiv 55: 102763.
- Arentz M, Yim E, Klaff L, Lokhndwala S, Riedo FX, et al. (2020) Characteristics and Outcomes of 21 Critically III Patients With COVID-19 in Washington State. JAMA 323: 1612-1614.
- Shahid Z, Kalayanamitra R, Mc Clafferty B, Kepko D, Ramgobin D, et al. (2020) COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 68: 926-929.
- Wang D, Hu B, Hu C, Zhu F, Liu X, et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumoniain Wuhan, China. JAMA 323: 1061-1069.
- 18. https://www.reccardioclinics.org/en-implicaciones-pandemia-por-covid-19-el-articulo-S2605153220300339.
- Liu K, Chen Y, Lin R, Han K (2020) Clinical features of COVID-19 in elderly patients: Acomparison with young and middle-aged patients. J Infect 80: e14-e18.
- 20. Little P (2020) Non-steroidal anti-inflammatory drugs and covid-19. BMJ 368:  $\rm m1185$ .
- 21. Sarangarajan R, Winn R, Kiebish MA, Bountra C, Granger E, et al. (2020) Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. J Racial Ethn Health Disparities 2020: 1-8.
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, et al. (2020) Hydroxy chloroquine and azithromycin as a treatment of COVID-19: Results of an open-labelnon-randomized clinical trial. Int J Antimicrob Agents 56: 105949.
- 23. Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet.
- 24. The Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, et al. (2020) Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. N Engl JMed. NEJMoa2021436.
- Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A Trial of Lopinavir-Ritonavirin Adults Hospitalized with Severe Covid-19. N Engl J Med 382: 1787-1799.
- Spinner CD, Gottlieb RL, Criner GJ, Lopz JRA, Cattelan AM, et al. (2020) Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA 324: 1048-1057.
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, et al. (2020) Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med 2020: NEJMoa2007764.
- 28. Horby P, Mafham M, Linsell L, Bell JL, Staplin L, et al. (2020) Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. medRXiv.
- The RECOVERY Collaborative Group (2020) Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet.



Advances In Industrial Biotechnology | ISSN: 2639-5665

Advances In Microbiology Research | ISSN: 2689-694X

Archives Of Surgery And Surgical Education | ISSN: 2689-3126

Archives Of Urology

Archives Of Zoological Studies | ISSN: 2640-7779

Current Trends Medical And Biological Engineering

International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X

Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276

Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292

Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370

Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594

Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X

Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562

Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608

Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879

Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397

Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751

Journal Of Aquaculture & Fisheries | ISSN: 2576-5523

Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780

Journal Of Biotech Research & Biochemistry

Journal Of Brain & Neuroscience Research

Journal Of Cancer Biology & Treatment | ISSN: 2470-7546

Journal Of Cardiology Study & Research | ISSN: 2640-768X

Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943

Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771

Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844

Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801

Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978

Journal Of Cytology & Tissue Biology | ISSN: 2378-9107

Journal Of Dairy Research & Technology | ISSN: 2688-9315

Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783

Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X

Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798

Journal Of Environmental Science Current Research | ISSN: 2643-5020

Journal Of Food Science & Nutrition | ISSN: 2470-1076

Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X

Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566

Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485

Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662

Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999

Journal Of Hospice & Palliative Medical Care

Journal Of Human Endocrinology | ISSN: 2572-9640

Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654

Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493

Journal Of Light & Laser Current Trends

Journal Of Medicine Study & Research | ISSN: 2639-5657

Journal Of Modern Chemical Sciences

Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044

Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X

Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313

Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400

Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419

Journal Of Obesity & Weight Loss | ISSN: 2473-7372

Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887

Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052

Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X

Journal Of Pathology Clinical & Medical Research

Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649

Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670

Journal Of Plant Science Current Research | ISSN: 2639-3743

Journal Of Practical & Professional Nursing | ISSN: 2639-5681

Journal Of Protein Research & Bioinformatics

Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150

Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177

Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574

Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060

 $Journal\ Of\ Surgery\ Current\ Trends\ \&\ Innovations\ |\ ISSN:\ 2578-7284$ 

Journal Of Toxicology Current Research | ISSN: 2639-3735

Journal Of Translational Science And Research

Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193

Journal Of Virology & Antivirals

Sports Medicine And Injury Care Journal | ISSN: 2689-8829

Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: https://www.heraldopenaccess.us/submit-manuscript